Premium
Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non‐Small Cell Lung Cancer to Receive Immunotherapy
Author(s) -
Mansfield AS,
Dong H
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.360
Subject(s) - immunotherapy , lung cancer , biomarker , programmed cell death , medicine , oncology , cell , pd l1 , cancer , cancer research , apoptosis , biology , biochemistry , genetics
The use of programmed cell death 1 ligand 1 (PD‐L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD‐1) or PD‐L1 inhibitors in non‐small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra‐ and intertumoral heterogeneity of expression. Although PD‐L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.